负荷量瑞舒伐他汀对非ST段抬高型急性冠脉综合征早期介入术后患者血管内皮功能的影响
x
请在关注微信后,向客服人员索取文件
篇名: | 负荷量瑞舒伐他汀对非ST段抬高型急性冠脉综合征早期介入术后患者血管内皮功能的影响 |
TITLE: | |
摘要: | 目的:评价负荷量瑞舒伐他汀对非ST段抬高型急性冠脉综合征(NSTE-ACS)早期介入术后患者血管内皮功能的影响。方法:128例NSTE-ACS并行早期介入术治疗的患者采用动态随机方法分为常规剂量组63例和负荷剂量组65例。术前,所有患者均给予硫酸氢氯吡格雷片300 mg和阿司匹林肠溶片100 mg。在此基础上,常规剂量组患者口服瑞舒伐他汀钙片10 mg,负荷剂量组患者口服瑞舒伐他汀钙片20 mg。术后,两组患者均连续口服瑞舒伐他汀钙片(10 mg)3个月,qd,并继续服用阿司匹林肠溶片(100 mg/d)和硫酸氢氯吡格雷片(75 mg/d)。分别于术前、术后8 h、术后24 h采集患者的血液标本,检测血清中肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTn)T、高敏C反应蛋白(hs-CRP)、内皮素(ET)和一氧化氮(NO)的水平;并记录患者术后3个月主要心血管事件的发生情况。结果:与术前比较,所有患者在术后8 h和术后24 h血清中的CK-MB、cTnT、hs-CRP和ET水平均显著升高,NO水平显著降低,差异有统计学意义(P<0.05);但负荷剂量组的变化幅度显著小于常规剂量组,差异有统计学意义(P<0.05)。两组患者的心血管事件发生率比较,差异无统计学意义(P>0.05)。结论:针对NSTE-ACS并行早期介入术治疗的患者,负荷剂量的瑞舒伐他汀保护作用更强,更能够抑制手术中引起的血管内皮细胞损伤。 |
ABSTRACT: | OBJECTIVE: To evaluate the effects of loading-dose rosuvastatin on vascular endothelial function in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) after early interventional therapy. METHODS: Totally of 128 NSTE-ACS patients underwent early interventional therapy were randomly divided into conventional dose group (63 cases) and loading dose group (65 cases). Before operation, all patients were given Clopidogrel sulfate tablets 300 mg and Aspirin enteric-coated tablets 100 mg; on this basis, conventional dose group was given Rosuvastatin calcium tablets 10 mg orally; loading dose group was given Rosuvastatin calcium tablets 20 mg orally. After PCI, both groups were given Rosuvastatin calcium tablets 10 mg orally, qd, and Aspirin enteric-coated tablets (100 mg/d) and Clopidogrel sulfate tablets (75 mg/d), for consecutive 3 months. The blood samples were collected before surgery, 8 h and 24 h after surgery. The serum levels of CK-MB, cTn T, hs-CRP, ET and NO were detected. The occurrence of major adverse cardiovascular events was recorded within 3 months after surgery. RESULTS: Compared with before surgery, the serum levels of CK-MB, cTn T, hs-CRP and ET were increased significantly 8 h and 24 h after surgery, while the level of NO was decreased, with statistical significance (P<0.05). However, the change range of loading dose group was lesser than that of conventional dose group, with statistical significance (P<0.05). There was no statistical significance in the incidence of adverse cardiovascular events between 2 groups (P>0.05). CONCLUSIONS: For NSTE-ACS patients underwent early interventional therapy, loading dose of rosuvastatin can protect the patients and inhibit the injury of vascular endothelial cell induced by the surgery. |
期刊: | 2016年第27卷第8期 |
作者: | 许向东,李宏松 |
AUTHORS: | XU Xiangdong,LI Hongsong |
关键字: | 瑞舒伐他汀;负荷剂量;经皮冠状动脉介入术;非ST段抬高型急性冠脉综合征;血管内皮细胞损伤 |
KEYWORDS: | Rosuvastatin; Loading dose; Percutaneous coronary intervention; Non-ST segment elevation acute coronary syndrome; Vascular endothelial cells injury |
阅读数: | 271 次 |
本月下载数: | 9 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!